Curanex Pharmaceuticals (CURX) Cash from Financing Activities (2025)
Curanex Pharmaceuticals' (CURX) quarterly Cash from Financing Activities came in at $14.9 million in Q3 2025.
Curanex Pharmaceuticals (CURX) Cash from Financing Activities (2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 1 years of Cash from Financing Activities data on file, last reported at $14.9 million in Q3 2025.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $14.9 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $14.9 million (changed N/A YoY) and the FY2025 annual result came in at $15.3 million, up 2329.57% from the prior year.
- Cash from Financing Activities was little changed at $14.9 million in Q3 2025.
- In the past five years, Cash from Financing Activities ranged from a high of $14.9 million in Q3 2025 to a low of $14.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Curanex Pharmaceuticals | 6.02 Mn | 1.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 14.91 Mn |
| Sep 30, 2025 | 14.91 Mn |